Tuyen Ong, M.D.
Tuyen is a physician, bioentrepreneur, and Ring’s CEO. Prior to joining Ring Therapeutics in September 2020, Tuyen served as Senior Vice President at Biogen and as Chief Development Officer at Nightstar Therapeutics until its acquisition by Biogen. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, investor, and M&A activities. Tuyen brings over 20 years of clinical and drug development experience from both large pharma and biotech, working in the fields of genetics, ophthalmology, and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer. Tuyen holds an M.D. from the University College London and an MBA from New York University Stern School of Business. He is a member of the Royal College of Ophthalmologists and a Churchill Fellow.